ST新研(300159.SZ):2023年度擬向金融機構及類金融企業申請不超20.776億元綜合授信額度
格隆匯12月19日丨ST新研(300159.SZ)公佈,公司於2022年12月19日召開第五屆董事會第四次會議,審議通過《關於2023年度向金融機構及類金融企業申請綜合授信額度暨預計擔保額度的議案》,同意公司及公司全資子公司、控股子公司及其下屬公司根據2023年度經營發展的需要,計劃向金融機構及類金融企業申請合計不超過20.776億元人民幣的綜合授信額度;為保證綜合授信融資方案的順利完成,同意公司及公司全資子公司、控股子公司在2023年度擬為合併報表範圍內的全資子公司、控股子公司及其下屬公司的上述綜合授信額度提供不超過20.776億元人民幣的擔保額度。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.